Zhengzhou

Az itteni vizsgálatok

Miről szól a helyszín 149 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek

• Tüdőrák38 vizsgálat
• Asztma13 vizsgálat
• Gyomor- és nyelőcsőrák11 vizsgálat
• Máj- és epeúti rák11 vizsgálat
• Áttétes emlőrák8 vizsgálat
• Petefészekrák8 vizsgálat
• Krónikus obstruktív tüdőbetegség (COPD)7 vizsgálat
• Krónikus vesebetegség7 vizsgálat
• Prosztatarák6 vizsgálat
• 2-es típusú cukorbetegség5 vizsgálat
• Gyermekkori daganatok5 vizsgálat
• Krónikus limfoid leukémia (CLL)5 vizsgálat
• és még 33

Fázis

• 3. fázis100 vizsgálat
• 2. fázis20 vizsgálat
• 1/2. fázis6 vizsgálat
• 4. fázis5 vizsgálat
• 1. fázis2 vizsgálat

Állapot

• Fut, nem toboroz59 vizsgálat
• Toboroz39 vizsgálat
• Lezárult24 vizsgálat
• Még nem toboroz20 vizsgálat
• Leállították6 vizsgálat
• Visszavonták1 vizsgálat

Fő szponzor

• AstraZeneca138 vizsgálat
• Acerta Pharma BV3 vizsgálat
• Alexion Pharmaceuticals, Inc.3 vizsgálat
• Dizal Pharmaceuticals2 vizsgálat
• Arcus Biosciences, Inc.1 vizsgálat
• és még 2

Futó vizsgálatok

• Még nem toboroz

  A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes

  NCT07922330· 3. fázis· AstraZeneca· Forrás

• Még nem toboroz

  A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients

  NCT07930507· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Observational Study of the Real-world Effectiveness and Safety of Selumetinib Treating Adult Patients With Neurofibromatosis Type 1 (NF1) Who Have Symptomatic, Inoperable Plexiform Neurofibroma (PN)

  NCT07888517· AstraZeneca· Forrás

• Toboroz

  Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer

  NCT07816666· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.

  NCT07686120· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus

  NCT07751848· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)

  NCT07596784· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás

  Contact: Alexion Pharmaceuticals, Inc. (Sponsor)

• Toboroz

  An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

  NCT07720284· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer

  NCT07538804· 1/2. fázis· Avistone Biotechnology Co., Ltd.· Forrás

• Toboroz

  A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

  NCT07662135· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

  NCT07662044· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

  NCT07667803· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study of AZD0292 in Chinese Participants With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

  NCT07774403· 2. fázis· AstraZeneca· Forrás

• Toboroz

  Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China

  NCT07593248· AstraZeneca· Forrás

• Toboroz

  A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

  NCT07652658· 2. fázis· AstraZeneca· Forrás

• Toboroz

  Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis

  NCT07516184· AstraZeneca· Forrás

• Toboroz

  Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.

  NCT07279935· 4. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab

  NCT07520162· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Implementation of Standardized Early Identification and Diagnosis for Transthyretin Amyloidosis (ATTR) in High-Risk Populations

  NCT07338942· AstraZeneca· Forrás

• Toboroz

  A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

  NCT07391657· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

  NCT07431281· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab

  NCT07363642· 3. fázis· AstraZeneca· Forrás

• Toboroz

  AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

  NCT07218809· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

  NCT07276581· 2. fázis· AstraZeneca· Forrás

• Toboroz

  Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China

  NCT07161388· AstraZeneca· Forrás

• Toboroz

  Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

  NCT07291037· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

  NCT07205822· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

  NCT07098338· 2. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma

  NCT07081633· 2. fázis· AstraZeneca· Forrás

• Toboroz

  Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

  NCT07044336· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Multicentre, Single Arm, Non-interventional, Real-world Study to Assess Demographic Characteristics and Patient Reported Outcomes in Patients With Severe Eosinophilic Asthma Treated With Benralizumab in China

  NCT06862206· AstraZeneca· Forrás

• Toboroz

  A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

  NCT07082738· 2. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Hyperkalemia Quality Improvement Program (HK-QIP) Study

  NCT06884267· AstraZeneca· Forrás

• Toboroz

  Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

  NCT06921785· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

  NCT06916806· 1. fázis· AstraZeneca· Forrás

• Toboroz

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

  NCT06868277· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

  NCT06742723· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

  NCT06764875· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

  NCT06564038· 1/2. fázis· AstraZeneca· Forrás

• Toboroz

  Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

  NCT06526793· 2. fázis· AstraZeneca· Forrás

• Toboroz

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

  NCT06627647· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

  NCT06692738· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT06417814· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  Volrustomig Priming Regimens Exploratory Phase II Platform Study

  NCT06448754· 2. fázis· AstraZeneca· Forrás

• Toboroz

  Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

  NCT06535607· 2. fázis· AstraZeneca· Forrás

• Toboroz

  Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

  NCT06467357· 3. fázis· AstraZeneca· Forrás

• Toboroz

  A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

  NCT06549595· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

  NCT06380751· 3. fázis· AstraZeneca· Forrás

• Toboroz

  JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

  NCT06386146· 1/2. fázis· Jacobio Pharmaceuticals Co., Ltd.· Forrás

  Contact: Jacobio Pharmaceuticals

• Toboroz

  A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

  NCT06455449· 3. fázis· AstraZeneca· Forrás

Showing 50 of 118.

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Tüdőrák12 toboroz
• Gyomor- és nyelőcsőrák5 toboroz
• 2-es típusú cukorbetegség4 toboroz
• Asztma4 toboroz
• Krónikus obstruktív tüdőbetegség (COPD)4 toboroz
• Petefészekrák4 toboroz
• Lupus (SLE)3 toboroz
• Máj- és epeúti rák3 toboroz
• Áttétes emlőrák2 toboroz
• Dermatomyositis and polymyositis (myositis)2 toboroz
• Elhízás2 toboroz
• Fej-nyaki daganatok2 toboroz
• Follikuláris limfóma2 toboroz
• Gyermekkori daganatok2 toboroz
• Krónikus limfoid leukémia (CLL)2 toboroz
• Krónikus vesebetegség2 toboroz
• Magas vérnyomás2 toboroz
• Méhnyakrák2 toboroz
• Méhtestrák2 toboroz
• Rheumatoid arthritis2 toboroz
• 1-es típusú cukorbetegség1 toboroz
• Akut limfoid leukémia (ALL)1 toboroz
• Bronchiectasis1 toboroz
• Chronic rhinosinusitis with nasal polyps1 toboroz
• Familiáris hiperkoleszterinémia1 toboroz
• Hodgkin-limfóma1 toboroz
• Hólyagrák1 toboroz
• Idiopátiás tüdőfibrózis1 toboroz
• Köpenysejtes limfóma1 toboroz
• Mezotelióma1 toboroz
• Mielóma multiplex1 toboroz
• Myasthenia gravis1 toboroz
• Neurofibromatosis type 11 toboroz
• Prosztatarák1 toboroz
• Tripla negatív emlőrák1 toboroz
• Vastagbélrák1 toboroz

Lezárt vizsgálatok

• Toboroz

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· 3. fázis· AstraZeneca· Forrás

• Lezárult

  Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

  NCT06750289· 3. fázis· AstraZeneca· Forrás

• Lezárult

  An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma Patients

  NCT06605885· AstraZeneca· Forrás

• Lezárult

  Establish FeNO Cut-off Value for Predicting Budesonide-formoterol Response in Chronic Cough Suggestive of CVA Patients.

  NCT06590740· 4. fázis· AstraZeneca· Forrás

• Lezárult

  A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

  NCT06502366· 3. fázis· AstraZeneca· Forrás

• Lezárult

  A Study To Evaluate The Treatment Pattern Of Moderate-to-Severe Asthma Patients In China

  NCT06422663· AstraZeneca· Forrás

• Lezárult

  Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM

  NCT06327815· 4. fázis· AstraZeneca· Forrás

• Lezárult

  DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9)

  NCT06539195· 2. fázis· Dizal Pharmaceuticals· Forrás

• Lezárult

  STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma

  NCT06465485· 3. fázis· AstraZeneca· Forrás

• Lezárult

  A Study to Evaluate the Consistency of Oscillometry and Spirometry Test Results in Patients With Confirmed or Suspected Asthma or COPD

  NCT06172777· AstraZeneca· Forrás

• Leállították

  Non-alcoholic Steatohepatitis Registry Platform Study

  NCT06123858· AstraZeneca· Forrás

• Lezárult

  A Real-world, Multi-center, Prospective, Observational Study for PNH in China

  NCT06154512· AstraZeneca· Forrás

• Lezárult

  A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).

  NCT06067828· 3. fázis· AstraZeneca· Forrás

• Toboroz

  Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

  NCT05797168· 1/2. fázis· AstraZeneca· Forrás

• Leállították

  ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

  NCT05746559· 3. fázis· Alexion Pharmaceuticals, Inc.· Forrás

• Lezárult

  A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

  NCT05568095· 3. fázis· Arcus Biosciences, Inc.· Forrás

• Lezárult

  Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).

  NCT05219162· 4. fázis· AstraZeneca· Forrás

• Leállították

  A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

  NCT05056727· 3. fázis· AstraZeneca· Forrás

• Lezárult

  Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)

  NCT04931563· 3. fázis· AstraZeneca· Forrás

• Lezárult

  Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens

  NCT04989816· 2. fázis· AstraZeneca· Forrás

• Leállították

  Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis

  NCT05006573· 3. fázis· AstraZeneca· Forrás

• Leállították

  Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

  NCT04847232· 3. fázis· AstraZeneca· Forrás

• Lezárult

  Evaluate the Safety Profile of BGF MDI in Chinese Patients With COPD in Routine Clinical Practice

  NCT04536402· AstraZeneca· Forrás

• Lezárult

  Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients

  NCT04560452· AstraZeneca· Forrás

• Lezárult

  Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)

  NCT04609904· 3. fázis· AstraZeneca· Forrás

• Lezárult

  Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

  NCT04053634· 3. fázis· AstraZeneca· Forrás

• Lezárult

  Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma

  NCT03927157· 3. fázis· AstraZeneca· Forrás

• Lezárult

  Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

  NCT03847428· 3. fázis· AstraZeneca· Forrás

• Lezárult

  Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

  NCT03534453· 3. fázis· AstraZeneca· Forrás

• Lezárult

  Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific

  NCT02442349· 2. fázis· AstraZeneca· Forrás

• Lezárult

  AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT02151981· 3. fázis· AstraZeneca· Forrás